Marta Llanos

Suggest Changes
Learn More
PURPOSE The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment(More)
4113 Background: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors. The(More)